{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:06:43Z","timestamp":1771330003606,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>In June 2022, French health authorities issued a universal recommendation for routine administration and reimbursement of rotavirus vaccines in infants. Given this recent recommendation by French health authorities, we sought to understand the public health impact of a universal rotavirus vaccination strategy compared with no vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>A deterministic, age-structured, nonlinear dynamic transmission model, accounting for herd immunity, was developed. We considered 3 vaccination coverage scenarios: high (95%), medium (75%) and low (55%). Model parameter values were based on published modeling and epidemiological literature. Model outcomes included rotavirus gastroenteritis (RVGE) cases and healthcare resource utilization due to RVGE (hospitalizations, general practitioner or emergency department visits), as well as the number needed to vaccinate to prevent 1 RVGE case (mild or severe) and 1 RVGE-related hospitalization. Model calibration and analyses were conducted using Mathematica 11.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Over 5 years following implementation, RVGE cases for children under 5 years are estimated to be reduced by 84% under a high vaccination coverage scenario, by 72% under a medium vaccination coverage scenario and by 47% under a low vaccination coverage scenario. Across all scenarios, the number needed to vaccinate to avert 1 RVGE case and hospitalization varied between 1.86\u20132.04 and 24.15\u201327.44, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Rotavirus vaccination with high vaccination coverage in France is expected to substantially reduce the number of RVGE cases and associated healthcare resource utilization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004448","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:03:14Z","timestamp":1719331394000},"page":"902-908","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Projected Public Health Impact of a Universal Rotavirus Vaccination Program in France"],"prefix":"10.1097","volume":"43","author":[{"given":"Sharomi","family":"Oluwaseun","sequence":"first","affiliation":[{"name":"From the BARDS-HEDS Department, Merck & Co., Inc, Rahway, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7776-1957","authenticated-orcid":false,"given":"Lauren","family":"Cagnan","sequence":"additional","affiliation":[{"name":"Market Access Department, MSD France, Courbevoie Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Xausa","sequence":"additional","affiliation":[{"name":"Wolfram Solutions Department, Wolfram Research Inc, Champaign, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Nachbar","sequence":"additional","affiliation":[{"name":"Wolfram Solutions Department, Wolfram Research Inc, Champaign, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Levy Bachelot","sequence":"additional","affiliation":[{"name":"CORE Regional, MSD France, Courbevoie Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Hsuan","family":"Chen","sequence":"additional","affiliation":[{"name":"MSD (UK) Limited, BARDS-HEDS, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Carias","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, CORE PL, Rahway, NJ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"17083","DOI":"10.1038\/nrdp.2017.83","article-title":"Rotavirus infection.","volume":"3","author":"Crawford","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1473-3099(17)30276-1","article-title":"Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015.","volume":"17","author":"Troeger","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.medmal.2005.08.007","article-title":"Morbidity and cost of rotavirus infections in France.","volume":"35","author":"Melliez","year":"2005","journal-title":"Med Mal Infect"},{"issue":"Suppl 1","key":"R5-20250614","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1086\/516716","article-title":"Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL study.","volume":"195","author":"Giaquinto","year":"2007","journal-title":"J Infect Dis"},{"key":"R7-20250614","first-page":"533","article-title":"Rotavirus vaccines: an update.","volume":"84","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.vaccine.2015.03.016","article-title":"Effectiveness and impact of rotavirus vaccines in Europe, 2006\u20132014.","volume":"33","author":"Karafillakis","year":"2015","journal-title":"Vaccine"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2021.1902808","article-title":"Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeqTM) postlicensure: a meta-analysis\u20142006\u20132020.","volume":"20","author":"Wang","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/infdis\/jiaa081","article-title":"Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019.","volume":"222","author":"Burnett","year":"2020","journal-title":"J Infect Dis"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/cid\/cix369","article-title":"Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006\u20132016.","volume":"65","author":"Jonesteller","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14760584.2018.1489724","article-title":"A decade of experience with rotavirus vaccination in the United States\u2013vaccine uptake, effectiveness, and impact.","volume":"17","author":"Pindyck","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/INF.0000000000001305","article-title":"Decrease of rotavirus gastroenteritis to a low level without resurgence for five years after universal RotaTeq vaccination in Finland.","volume":"35","author":"Hemming-Harlo","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1016\/j.vaccine.2017.08.052","article-title":"Impact of five years of rotavirus vaccination in Finland \u2013 and the associated cost savings in secondary healthcare.","volume":"35","author":"Leino","year":"2017","journal-title":"Vaccine"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2009.10.041","article-title":"RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.","volume":"28","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human\u2013bovine (WC3) reassortant rotavirus vaccine.","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/S2214-109X(19)30207-4","article-title":"Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008-16: findings from the global rotavirus surveillance network.","volume":"7","author":"Aliabadi","year":"2019","journal-title":"Lancet Glob Health"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jval.2016.05.011","article-title":"Cost-effectiveness of rotavirus vaccination in France\u2014accounting for indirect protection.","volume":"19","author":"Yamin","year":"2016","journal-title":"Value Health"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJM199610033351404","article-title":"Rotavirus infection in infants as protection against subsequent infections.","volume":"335","author":"Vel\u00e1zquez","year":"1996","journal-title":"N Engl J Med"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.vaccine.2007.11.064","article-title":"Cost and cost-effectiveness of childhood vaccination against rotavirus in France.","volume":"26","author":"Melliez","year":"2008","journal-title":"Vaccine"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1080\/21645515.2016.1274474","article-title":"Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand.","volume":"13","author":"Chen","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S0950268800029769","article-title":"Longitudinal study of rotavirus infections among children from Bel\u00e9m, Brazil.","volume":"102","author":"Linhares","year":"1989","journal-title":"Epidemiol Infect"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/147.1.95","article-title":"Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.","volume":"147","author":"Kapikian","year":"1983","journal-title":"J Infect Dis"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.1172330","article-title":"Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics.","volume":"325","author":"Pitzer","year":"2009","journal-title":"Science"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2013.170800","article-title":"Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination.","volume":"310","author":"Gasta\u00f1aduy","year":"2013","journal-title":"JAMA"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4161\/hv.7.5.15406","article-title":"Efficacy of the pentavalent rotavirus vaccine, RotaTeq\u00ae(RV5), between doses of a 3-dose series and with less than 3 doses incomplete regimen.","volume":"7","author":"Dennehy","year":"2011","journal-title":"Hum Vaccin"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/cid\/civ872","article-title":"Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012-2013.","volume":"61","author":"Payne","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1503\/cmaj.061709","article-title":"Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.","volume":"177","author":"Brisson","year":"2007","journal-title":"Can Med Assoc J"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14760584.2022.2075851","article-title":"Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review.","volume":"21","author":"Bencina","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1016\/j.vaccine.2007.06.015","article-title":"Burden of paediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with RotaTeq\u00ae in France.","volume":"25","author":"Huet","year":"2007","journal-title":"Vaccine"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.vaccine.2020.03.022","article-title":"Success of rotavirus vaccination in Finland, a register based study measuring impact beyond overall effectiveness.","volume":"38","author":"Solastie","year":"2020","journal-title":"Vaccine"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1473-3099(20)30058-X","article-title":"Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study.","volume":"20","author":"Quee","year":"2020","journal-title":"Lancet"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1016\/j.vaccine.2019.02.053","article-title":"A case-control study of risk factors for intussusception among infants in eastern France after the introduction of the rotavirus vaccine.","volume":"37","author":"Kamdem","year":"2019","journal-title":"Vaccine"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1016\/j.vaccine.2020.06.078","article-title":"Impact of rotavirus vaccination on intussusception hospital admissions in England.","volume":"38","author":"McGeoch","year":"2020","journal-title":"Vaccine"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1097\/INF.0000000000002656","article-title":"Impact of routine rotavirus vaccination in Germany: evaluation five years after its introduction.","volume":"39","author":"Marquis","year":"2020","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:06:31Z","timestamp":1749942391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004448","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}